UA66809C2 - Спосіб лікування гіперглікемії похідною тіазолідиндіону - Google Patents

Спосіб лікування гіперглікемії похідною тіазолідиндіону

Info

Publication number
UA66809C2
UA66809C2 UA2000042049A UA00042049A UA66809C2 UA 66809 C2 UA66809 C2 UA 66809C2 UA 2000042049 A UA2000042049 A UA 2000042049A UA 00042049 A UA00042049 A UA 00042049A UA 66809 C2 UA66809 C2 UA 66809C2
Authority
UA
Ukraine
Prior art keywords
hyperglycaemia
treatment
mammal
pharmaceutically acceptable
need
Prior art date
Application number
UA2000042049A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Робін Едвін Букінгем
Стефен Елістер Сміт
Original Assignee
Смітклайн Бічам Плс
Смитклайн Бичам Плс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Смітклайн Бічам Плс, Смитклайн Бичам Плс filed Critical Смітклайн Бічам Плс
Publication of UA66809C2 publication Critical patent/UA66809C2/uk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
UA2000042049A 1997-10-13 1998-10-12 Спосіб лікування гіперглікемії похідною тіазолідиндіону UA66809C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9721692.3A GB9721692D0 (en) 1997-10-13 1997-10-13 Novel treatment
PCT/GB1998/003067 WO1999018944A1 (fr) 1997-10-13 1998-10-12 Utilisation de thiazolidinediones pour le traitement de l'hyperglycemie

Publications (1)

Publication Number Publication Date
UA66809C2 true UA66809C2 (uk) 2004-06-15

Family

ID=10820481

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2000042049A UA66809C2 (uk) 1997-10-13 1998-10-12 Спосіб лікування гіперглікемії похідною тіазолідиндіону

Country Status (24)

Country Link
EP (1) EP1023057A1 (fr)
JP (1) JP2001519383A (fr)
KR (1) KR20010024482A (fr)
CN (1) CN1281358A (fr)
AP (1) AP1223A (fr)
AU (1) AU9547198A (fr)
BG (1) BG104405A (fr)
BR (1) BR9815220A (fr)
CA (1) CA2305289A1 (fr)
CZ (1) CZ20001298A3 (fr)
EA (1) EA200000418A1 (fr)
GB (1) GB9721692D0 (fr)
HR (1) HRP20000256A2 (fr)
HU (1) HUP0003673A3 (fr)
ID (1) ID24439A (fr)
IL (1) IL135515A0 (fr)
NO (1) NO20001897L (fr)
OA (1) OA11519A (fr)
PL (1) PL339804A1 (fr)
SK (1) SK5322000A3 (fr)
TR (1) TR200000957T2 (fr)
UA (1) UA66809C2 (fr)
WO (1) WO1999018944A1 (fr)
YU (1) YU28700A (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA11579A (en) * 1998-07-21 2004-06-01 Smithkline Beecham Plc Use of glucose uptake enhancer for reducing apoptosis.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3856378T2 (de) * 1987-09-04 2000-05-11 Beecham Group Plc Substituierte Thiazolidindionderivate
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5478852C1 (en) * 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus

Also Published As

Publication number Publication date
HUP0003673A2 (hu) 2001-10-28
NO20001897L (no) 2000-06-09
PL339804A1 (en) 2001-01-02
BG104405A (en) 2000-12-29
AU9547198A (en) 1999-05-03
HRP20000256A2 (en) 2000-12-31
EA200000418A1 (ru) 2000-10-30
NO20001897D0 (no) 2000-04-12
KR20010024482A (ko) 2001-03-26
EP1023057A1 (fr) 2000-08-02
TR200000957T2 (tr) 2000-08-21
WO1999018944A1 (fr) 1999-04-22
HUP0003673A3 (en) 2001-12-28
IL135515A0 (en) 2001-05-20
YU28700A (sh) 2003-10-31
CA2305289A1 (fr) 1999-04-22
BR9815220A (pt) 2000-11-14
GB9721692D0 (en) 1997-12-10
AP2000001788A0 (en) 2000-06-30
JP2001519383A (ja) 2001-10-23
ID24439A (id) 2000-07-20
CN1281358A (zh) 2001-01-24
AP1223A (en) 2003-11-13
OA11519A (en) 2004-02-09
SK5322000A3 (en) 2000-09-12
CZ20001298A3 (cs) 2001-08-15

Similar Documents

Publication Publication Date Title
AU3215597A (en) Method of inhibiting fibrosis with a somatostatin agonist
SG127714A1 (en) Method of treating metabolic disorders, especiallydiabetes, or a disease or condition associated wi th diabetes
EP1127579A3 (fr) Procedé permettant d'accroitre la biodisponibilité des compositions pharmaceutiques administrées par voie orale
WO2000016762A3 (fr) Procede pour reduire la dependance a la nicotine
PL325825A1 (en) Microemulsion for use as a carrier for administering active compounds
NZ514574A (en) Novel method of treatment
MXPA03003870A (es) Terapia de combinacion que comprende agentes antidiabeticos y anticonvulsionantes.
MX9602683A (es) Compuestos de 6-dimetilaminometil-1-fenil-ciclohexano como substancias farmaceuticamente activas.
ZA989744B (en) Method for administering acylated insulin.
CA2329004A1 (fr) Combinaison d'un sensibilisateur a l'insuline et d'un anorexigene pour le traitement ou la prevention du diabete
MY121517A (en) Anticonvulsant derivatives useful in reducing blood glucose levels
CA2339218A1 (fr) Procedes et compositions servant a augmenter la sensibilite a l'insuline
WO1999004772A3 (fr) Levobupivacine et son utilisation
CA2253130A1 (fr) Medicament pour traiter l'obesite et ameliorer le metabolisme lipidique
BG104059A (en) Diabetes treatment with rosiglytazone and insulin
CA2350659A1 (fr) Composition pharmaceutique de sensibilisateur modifiant la liberation d'insuline
BG101884A (en) Salts of the clavulanic acid
BG104058A (en) Diabetes treatment with thiazolydindion and sulphonylurea
UA66809C2 (uk) Спосіб лікування гіперглікемії похідною тіазолідиндіону
CA2234936A1 (fr) Composition pour traiter une affection intestinale inflammatoire par l'administration de n-acetylglucosamine par le colon et traitement connexe
AP9901720A0 (en) Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitors.
BG104139A (en) Diabetes treatment with thizolidindion and sulphonylurea
TW330933B (en) Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes
NZ503862A (en) Use of insulin sensitisers (especially thiazolidinediones) for the treatment of hyperglycaemia
MX9604692A (es) Derivados de quinoxalina para el tratamiento de tinnitus.